KalVista Pharmaceuticals (KALV) Non Operating Income (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Non Operating Income data on file, last reported at $1.1 million in Q3 2025.

• For the quarter ending Q3 2025, Non Operating Income fell 71.63% year-over-year to $1.1 million; the trailing twelve-month figure through Jul 2025 stood at $10.3 million (down 25.1% YoY), and the FY2025 full-year result was $7.9 million, down 42.45% from the prior year.
• Non Operating Income retreated to $1.1 million in Q3 2025, from $1.9 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $5.6 million in Q1 2023 to a low of $1.1 million in Q3 2025.
• A 5-year average of $3.4 million and a median of $3.6 million in 2022 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income surged 101.0% in 2023 and slumped 71.63% in 2025, its largest moves.
• Tracing KALV's Non Operating Income over 5 years: stood at $4.0 million in 2021, then decreased by 8.27% to $3.6 million in 2022, then tumbled by 42.2% to $2.1 million in 2023, then surged by 69.04% to $3.5 million in 2024, then plunged by 69.8% to $1.1 million in 2025.
• Business Quant data shows KALV's Non Operating Income at $1.1 million in Q3 2025, $1.9 million in Q2 2025, and $3.5 million in Q4 2024.